CNMD:NYE-CONMED Corporation (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 133.87

Change

-2.14 (-1.57)%

Market Cap

USD 3.97B

Volume

0.25M

Avg Analyst Target

USD 165.00 (+23.25%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida. Address: 11311 Concept Boulevard, Largo, FL, United States, 33773-4908

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

+1.20 (+0.99%)

USD214.85B 34.06 23.08
MDT Medtronic plc

+0.20 (+0.15%)

USD176.47B 49.36 25.53
SYK Stryker Corporation

-2.06 (-0.76%)

USD102.17B 49.65 29.13
EW Edwards Lifesciences Corporati..

+1.42 (+1.25%)

USD70.42B 49.17 59.18
BSX Boston Scientific Corporation

-0.34 (-0.74%)

USD65.19B 124.34 43.27
ZBH Zimmer Biomet Holdings, Inc

-9.30 (-5.71%)

USD34.07B 59.95 24.06
BIO-B Bio-Rad Laboratories, Inc

N/A

USD21.80B 5.21 3.85
BIO Bio-Rad Laboratories, Inc

+9.22 (+1.25%)

USD21.71B 5.49 3.91
SNN Smith & Nephew plc

-0.14 (-0.35%)

USD17.99B 32.48 22.74
PEN Penumbra, Inc

-3.12 (-1.18%)

USD9.71B 937.69 490.23

ETFs Containing CNMD

Symbol Name Weight Mer Price(Change) Market Cap
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.80 (+0.42%)

USD0.53B
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

-0.01 (-0.04%)

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.53% 74% C 70% C-
Dividend Return 0.36% 33% F 11% F
Total Return 19.88% 74% C 68% D+
Trailing 12 Months  
Capital Gain 62.48% 87% B+ 80% B-
Dividend Return 0.97% 33% F 15% F
Total Return 63.45% 87% B+ 79% C+
Trailing 5 Years  
Capital Gain 237.80% 69% D+ 94% A
Dividend Return 9.59% 57% F 32% F
Total Return 247.39% 69% D+ 94% A
Average Annual (5 Year Horizon)  
Capital Gain 29.84% 70% C- 89% B+
Dividend Return 1.20% 43% F 31% F
Total Return 31.04% 70% C- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 34.23% 43% F 30% F
Risk Adjusted Return 90.68% 65% D 89% B+
Market Capitalization 3.97B 48% F 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 78.85 31% F 10% F
Price/Book Ratio 5.54 32% F 18% F
Price / Cash Flow Ratio 61.47 20% F 5% F
EV/EBITDA 47.46 25% F 9% F
Management Effectiveness  
Return on Equity 7.63% 67% D+ 49% F
Return on Invested Capital 3.67% 60% D- 48% F
Return on Assets 3.76% 76% C 66% D
Debt to Equity Ratio 103.64% 5% F 35% F
Technical Ratios  
Short Ratio 8.46 20% F 6% F
Short Percent 6.20% 38% F 35% F
Beta 1.56 13% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.